NOVO NORDISK A S

Novo Nordisk A/S is a pharmaceutical manufacturer headquartered in Bagsvaerd, Denmark, that researches, develops, manufactures, and distributes prescription drugs across multiple therapeutic areas. The company operates through two primary segments: Obesity and Diabetes Care, which includes treatments for diabetes, obesity, cardiovascular conditions, and emerging therapy areas; and Rare Disease, which focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapies. Beyond pharmaceutical products, Novo Nordisk manufactures and markets medical devices including smart insulin pens (NovoPen 6 and NovoPen Echo Plus), growth hormone pens, injection needles, and digital applications for insulin dose guidance.

The company operates a global footprint spanning Europe, North America, Asia-Pacific, Latin America, the Middle East, and Africa, with particular presence in established markets including the United States, Japan, and Korea as well as emerging markets in mainland China and Southeast Asia. With approximately 68,794 full-time employees, Novo Nordisk operates as a large-scale pharmaceutical enterprise with integrated research, manufacturing, and commercial functions across multiple continents.